Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

NCT03662659 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03662659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03662659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Completed
Start date
October 16, 2018
Completion date
January 18, 2024
Enrollment
274 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the stomach, esophagogastric junction, gastric cancer